Skip to main content
. 2013 May;87(10):5858–5867. doi: 10.1128/JVI.00174-13

Fig 3.

Fig 3

Inhibition of C9 promoter activity by HCV genomic regions. (A) A C9 promoter luciferase construct (pGL3/C9 −786 to +40) was examined after cotransfection with an empty vector control, HCV core, NS2, NS3/4A, or NS5A in HepG2 cells for promoter activity. (B) C9 promoter luciferase activity was measured in the presence or absence of the HCV core genomic region transfected into HepG2 cells following stimulation with 1,000 U/ml IFN-γ, 40 ng/ml TNF-α, 20 ng/ml IL-1β, or 40 ng/ml IL-6. (C) IFN-γ-mediated dose-dependent stimulation of C9 promoter activity is shown after 18 h of treatment. **, P < 0.01; ***, P < 0.001 (for comparisons to empty vector-transfected or cytokine-treated cell results).